Aten Porus Lifesciences raises pre-series round

Bengaluru-based startup Avammune Therapeutics Inc. (a spin off from Aten Porus Lifesciences) secures a round of financing for completion of IND enabling studies for their Immuno-oncology asset. This funding will help advance Avammune’s highly diversified pipeline of best-in-class & firstin-class assets for oncology & autoimmune disorders. The round was led by JITO Angel Network, & other Investors. The startup is developing a novel class of drugs that harnesses the body’s first line of defence against pathogens to combat cancer. These highly effective drugs can potentially overcome the resistance to current drugs and due to their chemical nature can be taken by the patient as oral tablets and can be far more affordable than biological drugs. According to JITO Angel Network, the need for dedicated funding in the public health, therapeutic, preventive & curative medicine segment is underscored time & again by people, government & companies. Given that the antibodies market will grow by 20x in the upcoming decade, it just shows that companies like Avammune will only scale up.